Pulse Biosciences announced successful enrollment and treatment of two subjects in its first-in-human feasibility study for the ablation of cardiac tissue for the treatment of atrial fibrillation, and enrollment of its nano-PFA Cardiac Surgical System in the FDA's Total Product Life Cycle Advisory Program (TAP).